Innate Pharma

Orega Biotech

Orega Biotech Sas

Benjamin Rossi

Laurent Gauthier

Nadia Anceriz

Ariane Morel

Carine Paturel

Stéphanie Cornen

Nicolai Wagtmann

Hélène Sicard

Ivan Perrot

Nicolas Gourdin

Stéphanie Chanteux

Alessandro Moretta

Yannis Morel

Silvia Parolini

Simon Kollnberger

Stéphanie Zerbib

Nicolas Anfossi

Nicolaï Wagtmann

Helene Sicard

Stephanie Zerbib

Stephanie Cornen

Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Multispecific NK engager protein

The present invention relates to antigen-binding compounds that inhibit the enzymatic activity of soluble human CD39. The invention also relates to cells producing such compounds; methods of making such compounds, and antibodies, fragments, variants, and derivatives thereof; pharmaceutical compositions comprising the same; methods of using the compounds to diagnose, treat or prevent diseases, e.g., cancer.

Nucleic acids encoding and methods of producing proteins comprising antibody chains

NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Variable regions for NKp46 binding proteins

The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.

KIR3DL2 binding agents

NKp46 binding proteins

This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.

Siglec-9-neutralizing antibodies

Compositions and methods for treating cancer

This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.

Combination therapy using antibody to human Siglec-9 and antibody to human NKG2A for treating cancer

Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide

Multimeric multispecific proteins formed from dimerization between CH1 and CK domains and that bind two target antigens are provided. The proteins have advantages in production and in the treatment of disease, notably cancer or infectious disease.

Multispecific antigen binding proteins

This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.

Siglec-10 antibodies

Siglec neutralizing antibodies

NKp-46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.

Growing community of inventors

Marseilles, France

Benjamin Rossi